Department of Rheumatology, Leiden University Medical Center, Leiden, The Netherlands.
Rheumatology Unit, Department of Medicine Huddinge, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden.
Ann Rheum Dis. 2017 Jan;76(1):112-118. doi: 10.1136/annrheumdis-2015-208870. Epub 2016 Apr 26.
Anti-carbamylated protein (anti-CarP) antibodies are reported to associate with more radiographic progression within the total rheumatoid arthritis (RA) population and anti-citrullinated peptide antibody (ACPA)-negative subgroup. We explored the association of anti-CarP with radiographic progression in RA and aimed to replicate the association and evaluate the added value of anti-CarP antibodies in relation to ACPA and rheumatoid factor (RF).
576 Swedish and 628 Dutch patients with RA (2394 and 3247 sets of radiographs, respectively) were longitudinally studied. Replication was restricted to the Swedish patients. In both cohorts, the association of anti-CarP with radiographic progression was determined in strata of patients with similar ACPA and RF status; results of both cohorts were combined in fixed-effect meta-analyses. The net percentage of patients for whom the radiographic progression in 5 years was additionally correctly classified when adding anti-CarP to a model including ACPA and RF was evaluated.
Anti-CarP associated with radiographic progression in the total Swedish RA population (beta=1.11 per year, p=8.75×10) and in the ACPA-negative subgroup (beta=1.14 per year, p=0.034). Anti-CarP associated with more radiographic progression in the strata of ACPA-positive/RF-negative, ACPA-negative/RF-positive and ACPA-positive/RF-positive patients with RA (respective p values 0.014, 0.019 and 0.0056). A model including ACPA and RF correctly classified 54% and 57% of the patients; adding anti-CarP to this model did not increase these percentages (54% and 56% were correctly classified).
Anti-CarP antibodies associated with more severe radiographic progression in the total and ACPA-negative RA population. Anti-CarP-positivity had a statistically significant additive value to ACPA and RF, but did not improve correct classification of patients.
据报道,抗氨甲酰化蛋白(anti-CarP)抗体与整个类风湿关节炎(RA)人群和抗瓜氨酸化肽抗体(ACPA)阴性亚组内更多的放射学进展相关。我们探讨了抗 CarP 与 RA 放射学进展的相关性,并旨在复制这种相关性,评估抗 CarP 抗体相对于 ACPA 和类风湿因子(RF)的额外价值。
576 名瑞典和 628 名荷兰 RA 患者(分别有 2394 套和 3247 套放射照片)进行了纵向研究。复制仅限于瑞典患者。在两个队列中,在具有相似 ACPA 和 RF 状态的患者亚组中确定了抗 CarP 与放射学进展的相关性;两个队列的结果在固定效应荟萃分析中合并。当将抗 CarP 添加到包括 ACPA 和 RF 的模型中时,评估其额外正确分类 5 年内放射学进展的患者的净百分比。
抗 CarP 与瑞典 RA 总人群的放射学进展相关(每年增加 1.11,p=8.75×10)和 ACPA 阴性亚组(每年增加 1.14,p=0.034)。在 ACPA 阳性/RF 阴性、ACPA 阴性/RF 阳性和 ACPA 阳性/RF 阳性 RA 患者亚组中,抗 CarP 与更多的放射学进展相关(相应的 p 值分别为 0.014、0.019 和 0.0056)。包括 ACPA 和 RF 的模型正确分类了 54%和 57%的患者;将抗 CarP 添加到该模型中并没有增加这些百分比(分别有 54%和 56%的患者被正确分类)。
抗 CarP 抗体与整个 RA 人群和 ACPA 阴性 RA 人群的更严重放射学进展相关。抗 CarP 阳性具有统计学上显著的附加价值,优于 ACPA 和 RF,但并未改善患者的正确分类。